ANDERSON ELIZABETH M 4

What Happened

• Elizabeth M. Anderson, a director of Revolution Medicines (RVMD), was granted a total of 4,318 award shares on June 18, 2026: 1,191 restricted stock units (RSUs) and a 3,127-share derivative award (option/award) at $0.00 purchase price. No cash changed hands for these awards; the reported value is $0 at grant.

Key Details

• Transaction date: 2026-06-18; Filing date: 2026-06-23 (filed after the usual 2-business-day Section 16 reporting window).
• Awards: 1,191 RSUs (footnote: F1) and a 3,127-share derivative award/option (footnote: F3 describes vesting).
• Vesting/holding notes: F3 — the option/award vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting, subject to continued service. F2 notes the award is held by the David W. Anderson 1996 Irrevocable Trust.
• Shares owned following the transaction: not specified in the filing.
• Filing timeliness: The Form 4 was submitted June 23, 2026 (three business days after the grant), later than the typical 2-business-day deadline for Section 16 reporting.

Context

• These were grant/award transactions (code A) rather than open-market purchases or sales; awards like RSUs and option grants do not represent immediate economic gain until they vest/are settled and typically reflect compensation/retention practices rather than near-term trading intent.
• The derivative award appears to be an option-like grant with a clear vesting condition; it is not reported as a sale or exercise and was not immediately monetized.